

. 00270



Please type a plus sign (+) inside this box ->

PTO/SB/21 (08-00)

r		Application Number	09/700,329		Ann.			
TRANSMITTAL FORM			Filing Date	February 28	, 2001	8		
			First Named Inventor	P. Gevas, et	al.	33, 35		
(to be used for all correspondence after initial filing)			Group Art Unit	1631		0 00		
			Examiner Name	M. Borin		13		
Total Number of Pages in this 24 Submission		24	Attorney Docket Number	ACG2AUSA	A	25		
ENCLOSURES (check all that apply)								
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		☐ Assignment Papers (for an Application) ☐ Drawing(s) ☐ Licensing-related Papers ☐ Petition ☐ Petition to Convert to a Provisional Application ☐ Power of Attorney, Revocation Change of Correspondence Address ☐ Terminal Disclaimer ☐ Request for Refund		□ After Allowance Communication to Group □ Appeal Communication to Board of Appeals and Interferences □ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) □ Proprietary Information □ Status Letter □ Other Enclosure(s) (please identify below): . Response to Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure Statement To Support Filing and				
		Submission In Accordance with 37CFR§1.821 Through §1.825 RECEIVED MAY 0 3 2002 TECH CENTER 1600/2900						
			RECEIVED APR 26					
			MAY 0 3 2002 ECH CENTED 2002			TER 10		
TECH CENTER 1600/2900						1600/2900		
	SIG	NATURE C	DF APPLICANT, ATTORNE					
Firm <i>or</i> Individual Name	Mary E. Bak, HOWSON A		ON			EIVED		
Signature May E. Bh		SEP 1 2 2003						
Date April 25, 2002				TECH CENTER 1600/2900				
		C	ERTIFICATE OF MAILING	G				
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:								
Typed or printed name								
Signature				Date				



MAY 0 3 2002 A JECH GENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re t	he Application of) Group Art Unit: 1631		
P. Gev	vas et al.) Examiner: M. Borin		
Appln. No. 09/700,329)	8	
Filed:	February 28, 2001)	APR 2	CENTED CENTED
For:	PREVENTION AND TREATMENT OF HYPERGASTRINEMIA) April 25, 2002	5 PM 23	
Assist	SEQUENCE ant Commissioner for Patents ngton, DC 20231)	<u>ယ</u> ယ	72990

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE OF COMPLY WITH THE PATENT OF CONTAINING NUCLEOTIDE
SEQUE

Sir:

In a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", dated March 28, 2002, Applicant was informed that the above-identified application failed to comply with the requirements of 37 CFR § 1.821-1.825. Specifically, Applicant was informed that:

- (i) The application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR § 1.821(c);
- (ii) A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR § 1.821(e). A paper copy is in the file but is not in accordance with new Sequence Listing Rules; and
- (iii) Applicant is also requested to provide SEQ ID numbers for peptide sequences in the specification and claims.

In response to that Notice, Applicant asserts that pursuant to 37 CFR § 1.821-1.825, a paper copy of the "Sequence Listing", a computer readable form (CRF) of the "Sequence Listing", a Statement to Support Filing and Submission, and an Amendment inserting the Sequence ID numbers were originally filed with the application. As support, Applicant encloses herewith as Exhibits A-C, a copy of the stamped postcard indicating receipt by the US Patent and Trademark Office of the above-noted items, the originally filed paper copy of the "Sequence Listing", and the Preliminary Amendment inserting the sequence ID numbers into the originally filed application. Further, Applicant asserts that the paper copy filed with the application and enclosed herewith as Exhibit B did conform with the new Sequence Listing rules.

However, in an effort to expedite examination of this application and in response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" which was dated March 28, 2002, to which a response is due by April 28, 2002, enclosed herewith are:

- () Amendment under 37 CFR § 1.825;
 (X) Statement to Support Filing and Submission in accordance with 37 CFR §§ 1.821 through 1.825;
- () Original pages of the Sequence Listing;
- (X) Substitute copy of the pages of the Sequence Listing;
- () Original computer readable form of the Sequence Listing;
- (X) Substitute copy of the computer readable form of the Sequence Listing;
- (X) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- () Petition for a _____ month Extension of Time to Reply;
- () OTHER:

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for the Applicant

By Mary E. Bak Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477 Telephone: (215) 540-9206

Telefacsimile: (215) 540-5818

ACG2AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1631			
P. Gevas et al.) Examiner: M. Borin			
Appln. No. 09/700,329					
Filed: February 28, 2001					
For:	PREVENTION AND TREATMENT OF HYPERGASTRINEMIA	April 25, 2002 RECEIVED MAY 0 3 2002			
BOX S	SEQUENCE	TEALL OF NITED 4000/0000			
Assista	ant Commissioner for Patents	1EUN UENTER 1600/2900			
Washir	ngton, DC 20231	RECO			
	STATEMENT TO SUPPORT FILING	G AND SUBMISSION			
	IN ACCORDANCE WITH 37 CFR §1.	.821 THROUGH §1.87 CH CENTER 2003			
	STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §1.821 THROUGH §1.825 (X) I hereby state, in accordance with the requirements of 37 CFR §1.821(f) and to the best of my knowledge and belief that the Sequence				

- **(X)** §1.821(f) and to the best of my knowledge and belief that the Sequence Listing information recorded in computer readable form is identical to the written (on paper or compact disc) Sequence Listing, submitted pursuant to 37 CFR §1.821(c) and (e), respectively.
- **(X)** I hereby state that to the best of my knowledge and belief the submission filed in accordance with the requirements of 37 CFR §1.821(g), does not include new matter.
- ()I hereby state that to the best of my knowledge and belief the submission filed in accordance with the requirements of 37 CFR §1.821(h) does not include new matter or go beyond the disclosure of the international application as filed.
- () I hereby state that to the best of my knowledge and belief the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing do not include new matter. These amendments were made to conform with the current Sequence Listing Rules and to correct a typographical error in the Sequence Listing.

- () I hereby state that to the best of my knowledge and belief the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- () I hereby state that to the best of my knowledge and belief the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for the Applicant

Mary E/Bak
Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477

Telephone: (215) 540-9206 Telefacsimile: (215) 540-5818